In this article, we will discuss the 10 Best Stocks to Buy for the Next 15 Years.

On May 7, Fundstrat’s Tom Lee joined ‘Closing Bell’ on CNBC to discuss his outlook on the current stock market rally. Lee said that the risk-reward remains positive, arguing that stocks are rising for valid reasons, specifically citing strong earnings and the scarcity of compute within the supply chain, referencing semiconductors, energy, and AMD as prime examples. He noted that despite recent gains, the semi-index forward PE is only at 22x, which is lower than the 20-year high of 35x, suggesting that the leading stocks are not yet overpriced.

Lee observed that the risk-reward remains fairly balanced and pointed out that a significant amount of capital remained on the sidelines due to skepticism surrounding the start of the war. He attributed much of the current upward momentum to retail investors chasing moves in semiconductors and memory sectors. Lee also shared a recurring theme: AI is projected to add two percentage points to US GDP annually over the next 5 years, which translates to roughly 6% S&P earnings growth. He argued that AI provides a fundamental basis for earnings growth without inflation, creating a favorable environment for stocks. However, he acknowledged that rational investors remain cautious due to a looming shortage of petroleum products. This balance of logical caution and fundamental AI-driven growth supports his view of a market that can continue to climb.

Lee previously characterized a three-phase market where the S&P would reach 7,300 before facing headwinds and drifting into a bear market. He confirmed that he is still expecting a 15% to 20% drawdown (although a 10% pullback occurred when the war broke out), explaining that while 7,300 was once an aspirational level and there is fuel to move higher, the market must eventually confront two major triggers for turbulence: a test of the new Fed chair’s theories on inflation and the acute shortage of petroleum products resulting from the ongoing closure of the Strait. In conclusion, Lee views the current period as a bullish environment interrupted by mid-year turbulence.

Our Methodology

We sifted through financial media reports to compile a list of stocks widely discussed for their long-term potential, and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q4 2025.

Note: All data was sourced on May 7. 

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

10 Best Stocks to Buy for the Next 15 Years

10. SAP SE (NYSE:SAP)

Number of Hedge Fund Holders: 36

SAP SE (NYSE:SAP) is one of the best stocks to buy for the next 15 years. On May 4, SAP announced an agreement to acquire Dremio, which is a high-performance data lakehouse platform, to enhance its Business Data Cloud capabilities. This move aims to unify SAP and non-SAP data to support real-time analytical and AI workloads, specifically focusing on the advancement of agentic AI. The acquisition, which remains subject to regulatory approval, is expected to close in the third quarter of 2026.

By integrating Dremio, SAP Business Data Cloud will transition into an Apache Iceberg-native lakehouse, eliminating the need for data movement or format conversion. This open foundation allows for federated analytical reach across various enterprise data sources while leveraging the SAP HANA Cloud in-memory engine for operational performance. The platform’s serverless and elastic nature ensures it can scale automatically to meet demand, improving the overall economics and efficiency of enterprise analytics.

The collaboration will also introduce a universal, open catalog built on Apache Polaris to serve as a discovery and semantic layer. This unified system will provide a single point of access for business context, including relationships and data lineage, forming the basis for the SAP Knowledge Graph. SAP SE (NYSE:SAP) has committed to maintaining Dremio’s role as a steward of open-source projects like Apache Iceberg, Arrow, and Polaris to ensure continued innovation in governed, AI-ready intelligence.

SAP SE (NYSE:SAP) is a technology company that was founded in 1972 and is headquartered in Germany. The company primarily offers enterprise applications and business solutions.

9. AbbVie Inc. (NYSE:ABBV)

Number of Hedge Fund Holders: 84

AbbVie Inc. (NYSE:ABBV) is one of the best stocks to buy for the next 15 years. On April 30, AbbVie, in partnership with adMare BioInnovations, named RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award. This national competition is designed to support Quebec’s life sciences sector by supporting early-stage companies that align with AbbVie’s core therapeutic areas, such as immunology and oncology.

RIME Therapeutics was selected for its innovative “Disruptide” platform, which targets complex protein-protein interactions to accelerate drug discovery for inflammatory and immunological diseases. As part of the award, RIME Therapeutics will receive one year of laboratory and office space at the adMare Innovation Centre in Montreal, providing the startup with essential infrastructure and shared technical equipment.

Beyond physical space, the company will benefit from direct mentorship and expertise from AbbVie Inc.’s (NYSE:ABBV) scientific and business leadership. This collaboration is intended to help the startup transition its research from novel biological concepts into tractable chemical therapies more efficiently. Leadership from all three organizations emphasized the importance of fostering a collaborative ecosystem to scale Canadian life sciences companies globally.

AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.